Filing Details

Accession Number:
0001214659-18-001759
Form Type:
4
Zero Holdings:
No
Publication Time:
2018-03-02 18:08:18
Reporting Period:
2018-03-01
Accepted Time:
2018-03-02 18:08:18
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1576263 Mirati Therapeutics Inc. MRTX Pharmaceutical Preparations (2834) 462693615
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1579771 A Jamie Donadio C/O Mirati Therapeutics, Inc.
9393 Towne Centre Drive, Ste 200
San Diego CA 92121
Sr. Vp, Cfo No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2018-03-01 9,375 $5.50 9,375 No 4 M Direct
Common Stock Acquisiton 2018-03-01 12,500 $5.40 21,875 No 4 M Direct
Common Stock Acquisiton 2018-03-01 30,000 $7.30 51,875 No 4 M Direct
Common Stock Disposition 2018-03-01 25,600 $26.78 26,275 No 4 S Direct
Common Stock Disposition 2018-03-01 25,775 $27.45 500 No 4 S Direct
Common Stock Disposition 2018-03-01 500 $28.08 0 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 M Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Employee Stock Option (Right to Buy) Disposition 2018-03-01 9,375 $0.00 9,375 $5.50
Common Stock Employee Stock Option (Right to Buy) Disposition 2018-03-01 12,500 $0.00 12,500 $5.40
Common Stock Employee Stock Option (Right to Buy) Disposition 2018-03-01 30,000 $0.00 30,000 $7.30
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
20,625 2026-10-26 No 4 M Direct
37,500 2027-01-25 No 4 M Direct
0 2020-03-19 No 4 M Direct
Footnotes
  1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 21, 2017.
  2. 1/4th of the shares subject to the Option shall vest and become exercisable on the first anniversary of the date of grant, and 1/48th of the shares subject to the Option shall vest each month thereafter until fully vested.
  3. Twenty percent (20%) of the shares subject to the stock option vested and became exercisable on the grant date of the option (March 20, 2013), and an additional 20% shall vest and become exercisable each year on the anniversary of the grant date.
  4. This transaction was executed in multiple trades at prices ranging from $26.05 to $27.025. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  5. This transaction was executed in multiple trades at prices ranging from $27.05 to $28.00. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  6. This transaction was executed in multiple trades at prices ranging from $28.05 to $28.20. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.